孕烷X受体
骨肉瘤
药物代谢
化疗
抗药性
药理学
恶性肿瘤
药品
癌症研究
医学
肿瘤科
内科学
核受体
生物
生物化学
遗传学
转录因子
基因
作者
Kunhong Mao,Can Liu,Zhongwen Tang,Zhou-Zhou Rao,Jie Wen
标识
DOI:10.1080/03602532.2024.2366948
摘要
Osteosarcoma (OS) is a prevalent malignancy among adolescents, commonly manifesting during childhood and adolescence. It exhibits a high degree of malignancy, propensity for metastasis, rapid progression, and poses challenges in clinical management. Chemotherapy represents an efficacious therapeutic modality for OS treatment. However, chemotherapy resistance of OS is a major problem in clinical treatment. In order to treat OS effectively, it is particularly important to explore the mechanism of chemotherapy resistance in OS.The Pregnane X receptor (PXR) is a nuclear receptor primarily involved in the metabolism, transport, and elimination of xenobiotics, including chemotherapeutic agents. PXR involves three stages of drug metabolism: stage I: drug metabolism enzymes; stage II: drug binding enzyme; stage III: drug transporter.PXR has been confirmed to be involved in the process of chemotherapy resistance in malignant tumors. The expression of PXR is increased in OS, which may be related to drug resistance of OS. Therefore, wereviewed in detail the role of PXR in chemotherapy drug resistance in OS.
科研通智能强力驱动
Strongly Powered by AbleSci AI